Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Ethnic Bias In Medtech Review To Probe AI Algorithms And Regulatory Gaps

Executive Summary

There is potential for ethnic and socio-economic bias in medical device design, funding allocation and regulatory guidelines, according to the UK’s Department of Health and Social Care (DHSC), which has commissioned a review to uncover the extent of the problem.

You may also be interested in...



Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel